Protocol Review and Monitoring System ABSTRACT The City of Hope Comprehensive Cancer Center (COHCCC) has a well-established system for review, oversight, and support of cancer research conducted by its investigators. The system includes review by (1) Multidisciplinary Disease and Modality Teams for City of Hope (COH) investigator initiated concepts; (2) the Cancer Protocol Review and Monitoring Committee (CPRMC); (3) the Data Safety Monitoring Committee (DSMC); and (4) the COH designated Institutional Review Boards. The offices that support these committees are centralized within COH?s Research Protections Unit and respectively include the Protocol Scientific Review and Monitoring Office (PSRMO), the Data and Safety Monitoring Office (DSMO); and the Office for Human Research Subject Protections (OHRSP). The COHCCC Protocol Review and Monitoring System (PRMS) is focused on the scientific merit of protocols, prioritization and feasibility of trial completions, as well as oversight of the progress of approved research and termination of research that no longer meets criteria for ongoing continuation. The PRMS is overseen by the CPRMC, which coordinates with investigators and multidisciplinary Disease and/or Modality Teams. The CPRMC is administratively supported by the PSRMO. All proposed cancer research must be reviewed and approved by the CPRMC either through a convened review process or through expedited administrative scientific review for prioritization, as permitted by the CCSG for peer-reviewed research, and reviewed for scientific progress on at least an annual basis. The CPRMC has authority to close trials that do not demonstrate scientific progress, and all appeals are evaluated by the CPRMC. The PRMS continues under the leadership of Karen Reckamp, MS, MD, who has chaired the CPRMC since 2012. Dr. Reckamp is appointed by and reports directly to the Cancer Center Director. The PSRMO is under the direction of Amanda Hammond, JD, Sr. Director of the Research Protections Unit who reports to Ashley Baker Lee, COH?s Senior Vice President for Research Operations. The PRMS was conditionally approved in 2012 and received full approval in 2014.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-38
Application #
10059216
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
1997-08-01
Project End
2022-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
38
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Querfeld, Christiane; Leung, Samantha; Myskowski, Patricia L et al. (2018) Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile. Cancer Immunol Res 6:900-909
Liu, Xuxiang; Cao, Minghui; Palomares, Melanie et al. (2018) Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts. Breast Cancer Res 20:127
Das, Sadhan; Reddy, Marpadga A; Senapati, Parijat et al. (2018) Diabetes Mellitus-Induced Long Noncoding RNA Dnm3os Regulates Macrophage Functions and Inflammation via Nuclear Mechanisms. Arterioscler Thromb Vasc Biol 38:1806-1820
Al Malki, Monzr M; Nathwani, Nitya; Yang, Dongyun et al. (2018) Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24:1828-1835
Chiuppesi, Flavia; Nguyen, Jenny; Park, Soojin et al. (2018) Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice. J Virol 92:
Petrossian, Karineh; Kanaya, Noriko; Lo, Chiao et al. (2018) ER?-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer. Oncotarget 9:27736-27751
Ambaye, Nigus; Chen, Chih-Hong; Khanna, Swati et al. (2018) Streptonigrin Inhibits SENP1 and Reduces the Protein Level of Hypoxia-Inducible Factor 1? (HIF1?) in Cells. Biochemistry 57:1807-1813
Bosworth, Alysia; Goodman, Elizabeth L; Wu, Eric et al. (2018) The Minneapolis-Manchester Quality of Life Instrument: reliability and validity of the Adult Form in cancer survivors. Qual Life Res 27:321-332
Vu, Binh Thanh; Shahin, Sophia Allaf; Croissant, Jonas et al. (2018) Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer. Sci Rep 8:8524
Yan, Wei; Wu, Xiwei; Zhou, Weiying et al. (2018) Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nat Cell Biol 20:597-609

Showing the most recent 10 out of 1396 publications